News 2024-12-11
Porton and Aojin Collaborate to Advance XDC Drugs for Dual INDs
Recently, Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").
Porton will provide comprehensive CDMO services for Aojin in the CMC pharmaceutical research and GMP production of XDC conjugate drugs, targeting dual IND filings in China and the United States. Leveraging nearly two decades of end-to-end integrated CDMO service experiences, Porton has assembled a multidisciplinary project team that bridges drug substance and drug product technologies, integrating expertise in both small and large molecules. This strategic collaboration marks the beginning of a comprehensive and in-depth partnership between Porton and Aojin in the XDC conjugate drug sector. Together, we aim to promote the vigorous development of global XDC conjugate drugs, enabling the public’s early access to good medicines.
About Aojin Life Sciences
Aojin Life Sciences (Yixing) Co., Ltd. is a biotechnology company dedicated to developing precise drug delivery technology platforms and XDC conjugated drugs. It was jointly founded by Jiangsu Kingsly Pharmaceutical Co., Ltd. and Hong Kong OD Therapeutics, Ltd. The core technical management team brings over 30 years of experience in drug development with multinational corporations and biotech companies. Aojin Life Sciences possesses proprietary platform technology aimed at developing conjugated drugs that can deliver drugs in vivo with spatial and temporal control. By leveraging innovative technology, the company fundamentally improves the safety and efficacy of drugs, addresses urgent clinical challenges, and meets unmet clinical needs.
About Porton
With over 4300 employees,
Porton Pharma Solutions, a global company with R&D and GMP-compliant
manufacturing facilities across the US, EU and China, provides customer-centric
innovative and reliable CDMO solutions for Small Molecules, Tides, Biologics
and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal
Products from pre-clinical to commercial stages.
About Porton Biologics and Conjugates CDMO Platform
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
